Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company developing novel small molecule therapeutics to treat unmet needs in immune-mediated diseases, today announced that Chris Kirk, Chief Executive Officer and Co-founder, will participate in two upcoming investor conferences taking place in September:
- Event: 2025 Wells Fargo Healthcare Conference
Location: Boston, MA
Date/Time: Friday, September 5, 2025, at 11:00 am ET
Format: Fireside Chat
- Event: H.C. Wainwright 27 th Annual Global Investment Conference
Location: New York, NY
Date/Time: Monday, September 8, 2025, at 7:00 am ET
Format: Pre-Recorded On-Demand Presentation
A webcast of the fireside chat at the 2025 Wells Fargo Healthcare Conference will be available on the “Events & Presentations” section of the Company’s website at www.kezarlifesciences.com . Following the event, an archived webcast will be available on the Kezar website for 90 days.
About Kezar Life Sciences
Kezar Life Sciences is a clinical-stage biopharmaceutical company developing novel small molecule therapeutics to treat unmet needs in immune-mediated diseases. Zetomipzomib, a selective immunoproteasome inhibitor, is currently being evaluated for autoimmune hepatitis. This product candidate also has the potential to address multiple chronic immune-mediated diseases. For more information, visit www.kezarlifesciences.com , and follow us on LinkedIn , Facebook , Twitter and Instagram .
View source version on businesswire.com: https://www.businesswire.com/news/home/20250828473829/en/
/Amazon%20-%20Image%20by%20bluestork%20via%20Shutterstock.jpg)
/Micron%20Technology%20Inc_logo%20and%20website-by%20Mojahid%20Mottakin%20via%20Shutterstock.jpg)
/Salesforce%20Inc%20HQ%20building-by%20JHVEPhoto%20via%20Shutterstock.jpg)